Anastrozole on TRT: what the estrogen math actually shows

What did @adaclipsadmin actually say?

The creator argues that anastrozole should be a last resort on TRT, not a default add-on. His central claim: the drug's "number one side effect" is tanking HDL cholesterol, and stacking it with testosterone or anabolic steroids makes that drop severe enough that HDL can become "unmeasurable." He also calls cookie-cutter protocols combining testosterone, anastrozole, clomid, HCG, and tamoxifen "absolutely unethical" and "dangerous."

This is harm-reduction content aimed at men already using testosterone. The framing is practical rather than academic, and the core warnings deserve real scrutiny rather than dismissal.

Does the science back this up?

On HDL: yes, mostly. The aromatase inhibitor literature consistently shows that estrogen suppression lowers HDL, and testosterone alone already depresses it. Stacking the two compounds the problem.

A 2001 study by Leder et al. in the Journal of Clinical Endocrinology and Metabolism showed that aromatase inhibition in men significantly reduced HDL-C, independent of androgen levels. More directly relevant, Zmuda et al. (1993, Metabolism) demonstrated that estradiol plays a protective role in HDL metabolism in men, so blocking its synthesis predictably worsens the lipid profile. A 2020 review by Hackett and Kirby in Therapeutic Advances in Urology confirmed that TRT alone produces modest HDL reductions, with the effect amplified when estrogen is suppressed aggressively.

The claim of "unmeasurable" HDL is anecdotal and clinical, not published. But near-zero HDL values in heavily cycling bodybuilders are documented in case series. Baggish et al. (2010, Circulation) found severely dyslipidemic profiles in long-term anabolic steroid users, including HDL values under 20 mg/dL. "Unmeasurable" is likely hyperbolic but not biologically impossible at supraphysiologic doses.

What did they get wrong or right?

He got the HDL mechanism directionally right, but he misstated the lipoprotein name. He says "VHDL" rather than HDL or LDL. There is no standard lipoprotein called VHDL. He likely meant HDL (high-density lipoprotein), and context makes that clear, but the error is still sloppy for a clinician-facing audience.

He also says "we have no idea how" anastrozole harms HDL directly. That is an overstatement. The mechanism is not fully resolved, but reduced estradiol is known to decrease hepatic lipase activity and impair reverse cholesterol transport, both of which lower HDL. Saying there is no mechanism is inaccurate. The mechanism is incomplete, not absent.

On the ethics of cookie-cutter protocols: he is on solid ground. Blanket prescribing of anastrozole to all TRT patients without individualized estrogen monitoring contradicts the Endocrine Society's 2018 clinical practice guidelines, which do not recommend routine aromatase inhibitor use in hypogonadal men.

What should you actually know?

Anastrozole is FDA-approved for breast cancer, not for TRT-related estrogen management. Its off-label use in men is common but not guideline-supported as a routine co-prescription. If you are on TRT and a provider is automatically pairing it with an aromatase inhibitor without checking your actual estradiol levels, that is a red flag worth questioning.

HDL suppression matters. HDL under 40 mg/dL is an independent cardiovascular risk factor. Men combining anabolic steroids with aromatase inhibitors for extended periods are accumulating cardiovascular risk that may not show up for years. The Baggish et al. data showing early coronary artery disease in long-term AAS users is not just a gym cautionary tale: it is prospective imaging data.

Estradiol in men is not purely a problem to suppress. It contributes to bone density, libido, cardiovascular protection, and cognitive function. Driving it to near-zero with aggressive anastrozole use has real costs, not just theoretical ones.

• Do not accept a standing anastrozole prescription without periodic lipid panels and estradiol levels.
• HDL below 20 mg/dL warrants immediate clinical reassessment regardless of estradiol values.
• The combination of supraphysiologic testosterone plus an aromatase inhibitor is not a harm-reduction stack. It is a cardiovascular risk amplifier.